AngioDynamics Inc. (ANGO)

16.83
0.06 0.36
NASDAQ : Health Technology
Prev Close 16.77
Open 16.77
Day Low/High 16.77 / 17.31
52 Wk Low/High 14.80 / 18.85
Volume 149.14K
Avg Volume 226.10K
Exchange NASDAQ
Shares Outstanding 36.74M
Market Cap 607.76M
EPS 0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Relative Strength Alert For AngioDynamics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AngioDynamics Reports Fiscal 2018 Second Quarter Financial Results

AngioDynamics Reports Fiscal 2018 Second Quarter Financial Results

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced financial results for the...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EVA, FSBC, GTE, SND, UWN Downgrades: ANGO, PCG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

AngioDynamics To Present At The J.P. Morgan Healthcare Conference

AngioDynamics To Present At The J.P. Morgan Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Jim Clemmer,...

AngioDynamics To Report Fiscal 2018 Second Quarter Financial Results On January 4, 2018

AngioDynamics To Report Fiscal 2018 Second Quarter Financial Results On January 4, 2018

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANGO, NKSH, OBCI, RGS, SGMA Downgrades: AIG, GGP Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of AngioDynamics, Inc.

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of AngioDynamics, Inc.

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against AngioDynamics, Inc.

ANGO: Insiders vs. Shorts

The most recent short interest data was recently released for the 06/30/2017 settlement date, and AngioDynamics Inc is one of the most shorted stocks of the Russell 3000, based on 6.90 "days to cover" versus the median component at 4.17. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

ANGIODYNAMICS (ANGO) INVESTOR ALERT: Legal Investigation For Potential Securities Law Violations

ANGIODYNAMICS (ANGO) INVESTOR ALERT: Legal Investigation For Potential Securities Law Violations

Girard Gibbs LLP is investigating potential claims on behalf of investors of AngioDynamics, Inc.

AngioDynamics Becomes Oversold (ANGO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: C (Hold)